Usefulness of the Stroke Drivers Screening Assessment (SDSA) in patients with Parkinson’s syndrome (P2.8-041)

Objective: It is important to find out the clinical screening battery to predict the fitness to drive in patients with Parkinson’s syndrome (PS). Background: Nouri et al. developed the Stroke Drivers Screening Assessment (SDSA), which was found predictive of on-road driving performance in stroke patients. There are some previous reports about validation of the SDSA for patients with Multiple sclerosis, Dementia and Parkinson’s disease. However, there is not enough consensus on application of the SDSA to predict the driving ability of patients with PS. In this study, we investigated the validity of using the SDSA for PS patients by comparing the results of a high-fidelity driving simulator (DS). Design/Methods: 29 PS patients [16 males, 13 female, 20 of Parkinson disease (PD), six progressive supranuclear palsy (PSP), three dementia with Lewy bodies (DLB), one multiple system atrophy-parkinson type (MSA-P) and one vascular-parkinsonism (VP)] were assessed on the Japanese version of the SDSA plus additional cognitive tests and the DS (Honda Safety Navi®). The results of the DS were used as measures of driving ability. All participants were active drivers with driver’s license. Results: 16 out of 29 participants were predicted to be suitable for driving by the DS. On the other hand, 11 out of 29 participants failed in the SDSA. The SDSA predicted participant’s performance on the DS with 69% accuracy, 56% sensitivity, and 85% specificity. Moreover, various parameters of the DS significantly correlated with the SDSA score. Conclusions: The SDSA battery has the potential to be a screening tool to select the drivers who have the fitness to continue driving in patients with PS. Larger studies are needed to definitively establish its predictive accuracy and confirm the validity of the predictions. Disclosure: Dr. Morimoto has nothing to disclose.